JP2016525572A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525572A5
JP2016525572A5 JP2016531580A JP2016531580A JP2016525572A5 JP 2016525572 A5 JP2016525572 A5 JP 2016525572A5 JP 2016531580 A JP2016531580 A JP 2016531580A JP 2016531580 A JP2016531580 A JP 2016531580A JP 2016525572 A5 JP2016525572 A5 JP 2016525572A5
Authority
JP
Japan
Prior art keywords
dispersible film
film according
concentration
intraoral
dispersible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016531580A
Other languages
Japanese (ja)
Other versions
JP6294479B2 (en
JP2016525572A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/PT2014/000050 external-priority patent/WO2015016727A2/en
Publication of JP2016525572A publication Critical patent/JP2016525572A/en
Publication of JP2016525572A5 publication Critical patent/JP2016525572A5/ja
Application granted granted Critical
Publication of JP6294479B2 publication Critical patent/JP6294479B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (27)

(i)フィルム形成性ポリマー、ここでフィルム形成性ポリマーはポリ酢酸ビニルであり、口内分散性フィルムにおけるポリ酢酸ビニルの濃度は30〜95重量%である、(ii)崩壊剤および(iii)ポリビニルアルコール(PVA)またはヒドロキシプロピルメチルセルロース(HPMC)を包含する、口内分散性フィルム。 (I) a film-forming polymer, wherein the film-forming polymer is polyvinyl acetate and the concentration of polyvinyl acetate in the mouth-dispersible film is 30-95% by weight; (ii) a disintegrant and (iii) polyvinyl It encompasses alcohol (PVA) or hydroxypropylmethyl cellulose (HPMC), orodispersible film. 崩壊剤が、(i)セルロース誘導体、(ii)セルロースエーテル、(iii)カルボキシメチルセルロースまたはその塩、または、(iv)カルボキシメチルセルロースナトリウムである、請求項1に記載の口内分散性フィルム。 The mouth dispersible film according to claim 1, wherein the disintegrant is (i) a cellulose derivative, (ii) a cellulose ether, (iii) carboxymethylcellulose or a salt thereof, or (iv) sodium carboxymethylcellulose. 1種または2種以上の分散剤をさらに包含する、請求項1または2に記載の口内分散性フィルム。 The intraoral dispersible film according to claim 1 or 2 , further comprising one or more dispersants . 1種または2種以上の分散剤が、(i)ラウリル硫酸ナトリウム、(ii)ポビドン、(iii)マクロゴールセトステアリルエーテル、および、(iv)ソルビン酸および水酸化ナトリウムのうち1種または2種以上を包含する、請求項に記載の口内分散性フィルム。 One or more dispersants are (i) sodium lauryl sulfate, (ii) povidone, (iii) macrogolcetostearyl ether, and (iv) one or two of sorbic acid and sodium hydroxide. including more, orodispersible film according to claim 3. 可塑剤をさらに包含する、請求項1および3のいずれか一項に記載の口内分散性フィルム。 The intra-oral dispersible film according to any one of claims 1 and 3 , further comprising a plasticizer. 可塑剤が、(i)シトラート誘導体、(ii)クエン酸トリエチル、(iii)グリセロール、(iv)ポリエチレングリコールまたは(v)プロピレングリコールである、請求項に記載の口内分散性フィルム。 Plasticizer, (i) citrate derivatives, (ii) triethyl citrate, (iii) glycerol, (iv) a polyethylene glycol or (v) profiles propylene glycol, orodispersible film according to claim 5. 口内分散性フィルムにおけるポリビニルアルコールまたはヒドロキシプロピルメチルセルロースのうち少なくとも1種の濃度、5〜17.5重量%である、請求項1〜6のいずれか一項に記載の口内分散性フィルム。 The intra-oral dispersible film according to any one of claims 1 to 6 , wherein the concentration of at least one of polyvinyl alcohol and hydroxypropyl methylcellulose in the intra- oral dispersible film is 5 to 17.5% by weight. (i)1種または2種以上の甘味料、(ii)1種または2種以上の着色剤、(iii)1種または2種以上の香味剤および(iv)1種または2種以上の唾液分泌促進薬のうち1種または2種以上をさらに包含する、請求項1〜7のいずれか一項に記載の口内分散性フィルム。 (I) one or more sweeteners, (ii) one or more colorants, (iii) one or more flavorings, and (iv) one or more salivas. The intra-oral dispersible film according to any one of claims 1 to 7 , further comprising one or more of secretagogues. 口内分散性フィルムにおけるポリビニルアルコールまたはヒドロキシプロピルメチルセルロースの濃度が1〜21重量%であり;および、
崩壊剤が、カルボキシメチルセルロースナトリウムであり、ここで口内分散性フィルムにおけるカルボキシメチルセルロースナトリウムの濃度が1〜22重量%であり;
口内分散性フィルム全構成要素の総重量百分率が100%を超えない、請求項1〜8のいずれか一項に記載の口内分散性フィルム。
Concentration of Po polyvinyl alcohol or hydroxypropylmethyl cellulose in orodispersible film is 1 to 21 wt%; and,
Disintegrant, carboxymethyl a cellulose sodium, wherein a 1 to 22 wt% concentration of sodium carboxymethyl cellulose in orodispersible film;
The intraoral dispersible film according to any one of claims 1 to 8 , wherein the total weight percentage of all components of the intraoral dispersible film does not exceed 100%.
口内分散性フィルムにおけるポリ酢酸ビニルの濃度、30〜60重量%である、請求項に記載の口内分散性フィルム。 The intraoral dispersible film according to claim 9 , wherein the concentration of polyvinyl acetate in the intraoral dispersible film is 30 to 60% by weight. 口内分散性フィルムにおけるポリビニルアルコールまたはヒドロキシプロピルメチルセルロースの濃度、5〜17.5重量%である、請求項10に記載の口内分散性フィルム。 The concentration of polyvinyl alcohol or hydroxypropyl methyl cellulose in orodispersible film is from 5 to 17.5 wt%, orodispersible film of claim 10. 可塑剤をさらに包含する、請求項11に記載の口内分散性フィルム。 The intra-oral dispersible film according to claim 11 , further comprising a plasticizer. 医薬品、ニュートラシューティカル剤、サプリメントまたは美容用薬剤である活性剤をさらに包含する、請求項1〜12のいずれか一項に記載の口内分散性フィルム。The intra-oral dispersible film according to any one of claims 1 to 12, further comprising an active agent which is a pharmaceutical, a nutraceutical agent, a supplement or a cosmetic agent. フィルムを、崩壊させるのに充分な期間、口腔内に配置することを包含する、請求項1〜13のいずれか一項に記載の口内分散性フィルムを送達する方法。14. A method for delivering an orally dispersible film according to any one of claims 1 to 13, comprising placing the film in the oral cavity for a period of time sufficient to disintegrate. 口腔粘膜に接した口内分散性フィルムの崩壊時間が90秒未満かまたはそれと等しい、請求項1〜13のいずれか一項に記載の口内分散性フィルム。The dispersible film in any one of claims 1 to 13, wherein the disintegration time of the dispersible film in contact with the oral mucosa is less than or equal to 90 seconds. 口腔粘膜に接した口内分散性フィルムの崩壊時間が45秒未満かまたはそれと等しい、請求項1〜15のいずれか一項に記載の口内分散性フィルム。The mouth-dispersible film according to any one of claims 1 to 15, wherein the disintegration time of the mouth-dispersible film in contact with the oral mucosa is less than or equal to 45 seconds. 口内分散性フィルムにおけるポリ酢酸ビニルの濃度が30〜60重量%である、請求項1〜13、15および16のいずれか一項に記載の口内分散性フィルム。The intraoral dispersible film according to any one of claims 1 to 13, 15 and 16, wherein the concentration of polyvinyl acetate in the intraoral dispersible film is 30 to 60% by weight. 口内分散性フィルムにおける崩壊剤の濃度が1〜22重量%である、請求項1〜13、15〜17のいずれか一項に記載の口内分散性フィルム。The mouth dispersible film according to any one of claims 1 to 13, 15 to 17, wherein a concentration of the disintegrant in the mouth dispersible film is 1 to 22% by weight. 口内分散性フィルムにおける崩壊剤の濃度が5〜17.5重量%である、請求項1〜13、15〜19のいずれか一項に記載の口内分散性フィルム。The mouth-dispersible film according to any one of claims 1 to 13, 15 to 19, wherein a concentration of the disintegrant in the mouth-dispersible film is 5 to 17.5% by weight. 口内分散性フィルムにおけるポリビニルアルコールまたはヒドロキシプロピルメチルセルロースの少なくとも1つの濃度が1〜21重量%である、請求項1〜13、15〜19のいずれか一項に記載の口内分散性フィルム。The intraoral dispersible film according to any one of claims 1 to 13, 15 to 19, wherein the concentration of at least one of polyvinyl alcohol or hydroxypropylmethylcellulose in the intraoral dispersible film is 1 to 21% by weight. 口内分散性フィルムにおけるポリビニルアルコールまたはヒドロキシプロピルメチルセルロースの少なくとも1つの濃度が5〜17.5重量%である、請求項1〜13、15〜19のいずれか一項に記載の口内分散性フィルム。The mouth-dispersible film according to any one of claims 1 to 13, 15 to 19, wherein the concentration of at least one of polyvinyl alcohol or hydroxypropylmethylcellulose in the mouth-dispersible film is 5 to 17.5% by weight. 口内分散性フィルムにおける1種または2種以上の分散剤の濃度が0.001〜10重量%である、請求項3〜13、15〜21のいずれか一項に記載の口内分散性フィルム。The intraoral dispersible film according to any one of claims 3 to 13, 15 to 21, wherein the concentration of the one or more dispersants in the intraoral dispersible film is 0.001 to 10% by weight. 口内分散性フィルムにおける可塑剤の濃度が1〜20重量%である、請求項5〜13、15〜22のいずれか一項に記載の口内分散性フィルム。The intraoral dispersible film according to any one of claims 5 to 13 and 15 to 22, wherein the concentration of the plasticizer in the intraoral dispersible film is 1 to 20% by weight. ポリビニルアルコールまたはヒドロキシプロピルメチルセルロースがポリビニルアルコールである、請求項1〜13、15〜23のいずれか一項に記載の口内分散性フィルム。The intraoral dispersible film according to any one of claims 1 to 13, 15 to 23, wherein the polyvinyl alcohol or hydroxypropylmethylcellulose is polyvinyl alcohol. ポリビニルアルコールまたはヒドロキシプロピルメチルセルロースがヒドロキシプロピルメチルセルロースである、請求項1〜13、15〜23のいずれか一項に記載の口内分散性フィルム。The intraoral dispersible film according to any one of claims 1 to 13, 15 to 23, wherein the polyvinyl alcohol or hydroxypropylmethylcellulose is hydroxypropylmethylcellulose. (1)口内分散性フィルムにおけるポリ酢酸ビニルの濃度対(2)口内分散性フィルムにおけるポリビニルアルコールまたはヒドロキシプロピルメチルセルロースの濃度の重量比が、20:1〜1:1である、請求項1〜13、15〜25のいずれか一項に記載の口内分散性フィルム。The weight ratio of (1) the concentration of polyvinyl acetate in the mouth-dispersible film to (2) the concentration of polyvinyl alcohol or hydroxypropyl methylcellulose in the mouth-dispersible film is 20: 1 to 1: 1. The intraoral dispersible film according to any one of 15 to 25. 医薬品、ニュートラシューティカル剤、サプリメントまたは美容用薬剤である活性剤をさらに包含する、請求項9に記載の口内分散性フィルム。The intra-oral dispersible film according to claim 9, further comprising an active agent which is a pharmaceutical, a nutraceutical agent, a supplement or a cosmetic agent.
JP2016531580A 2013-07-31 2014-07-31 Oral dispersible film Active JP6294479B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361860516P 2013-07-31 2013-07-31
US61/860,516 2013-07-31
PCT/PT2014/000050 WO2015016727A2 (en) 2013-07-31 2014-07-31 Oral dispersible films

Publications (3)

Publication Number Publication Date
JP2016525572A JP2016525572A (en) 2016-08-25
JP2016525572A5 true JP2016525572A5 (en) 2017-09-07
JP6294479B2 JP6294479B2 (en) 2018-03-14

Family

ID=51535496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016531580A Active JP6294479B2 (en) 2013-07-31 2014-07-31 Oral dispersible film

Country Status (8)

Country Link
US (1) US9603935B2 (en)
EP (1) EP3027172B1 (en)
JP (1) JP6294479B2 (en)
CN (1) CN105682639B (en)
BR (1) BR112016002205A2 (en)
ES (1) ES2835258T3 (en)
HK (1) HK1225624A1 (en)
WO (1) WO2015016727A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8701671B2 (en) 2011-02-04 2014-04-22 Joseph E. Kovarik Non-surgical method and system for reducing snoring
US9549842B2 (en) 2011-02-04 2017-01-24 Joseph E. Kovarik Buccal bioadhesive strip and method of treating snoring and sleep apnea
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11357722B2 (en) 2011-02-04 2022-06-14 Seed Health, Inc. Method and system for preventing sore throat in humans
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
CA3044944C (en) * 2015-11-25 2021-06-22 Tbm Company Film for oral hemostasis and wound protection
MX2018012587A (en) * 2016-04-14 2019-03-07 Sensorion (+)-azasetron for use in the treatment of ear disorders.
CN106619577A (en) * 2016-10-08 2017-05-10 中国药科大学 Novel loratadine oral quickly soluble film and preparation method thereof
RU2751193C2 (en) 2017-01-11 2021-07-12 Ферринг Б.В. Fast decoring pharmaceutical composition
US11154585B2 (en) * 2017-01-18 2021-10-26 Pharmathen S.A. Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
US20200197366A1 (en) * 2017-08-08 2020-06-25 Kashiv Biosciences, Llc Pharmaceutical composition comprising eliglustat
US11235013B2 (en) * 2018-09-04 2022-02-01 Babak Ghalili Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
US11185526B2 (en) * 2018-09-04 2021-11-30 Babak Ghalili Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
CN108785289A (en) * 2018-09-06 2018-11-13 北京太阳升高科医药研究股份有限公司 Molten film of naratriptan hydrochloride mouth and preparation method thereof
CN111166730A (en) * 2018-11-13 2020-05-19 杨守忠 Quick-release orally-dissolvable film of amantadine hydrochloride and preparation method and application thereof
IT201800020185A1 (en) * 2018-12-19 2020-06-19 Davide Fiumi FORMULATIONS CONTAINING VITAMIN D3 IN EDIBLE FILM FOR THE TREATMENT OF PATIENTS WITH MALABSORPTION
CN109793201B (en) * 2019-03-26 2022-08-09 武汉轻工大学 Natural compound sweetener, preparation method thereof and novel extruded gluten
CN112569208B (en) * 2019-09-29 2023-10-31 四川科伦药物研究院有限公司 Pramipexole dihydrochloride pharmaceutical composition and preparation method thereof
US20210187858A1 (en) * 2019-12-18 2021-06-24 Dieu Cam Vuong Method and system for manufacturing of pharmaceutical formulas in form of orally disintegrating films (odf)
CN111388455B (en) * 2020-04-09 2022-09-02 沈阳药科大学 Everolimus oral film and preparation method thereof
US20230330036A1 (en) * 2022-04-13 2023-10-19 Oak Therapeutics, Inc. Long acting, continuous oral release from oral dispersing strips (ods) addressing the need for high dosage of active ingredients
WO2023230430A1 (en) * 2022-05-21 2023-11-30 Neuvision Development Llc Topical ocular administration of ambroxol for ocular pain
CN114886877B (en) * 2022-06-16 2024-02-02 北京海泰天正医药科技有限公司 Olanzapine Ping Fu sittin compound oral solution film and preparation method thereof
CN114983984B (en) * 2022-07-26 2023-09-01 山东达因海洋生物制药股份有限公司 Compound oral film for treating asthma and preparation method thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2656338B2 (en) * 1989-01-31 1997-09-24 日東電工株式会社 Oral mucosa patch preparation
DE19961897A1 (en) * 1999-12-20 2001-06-28 Basf Ag Use of a film coating as a taste masking coating of pharmaceutical dosage forms
US6585997B2 (en) * 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
CA2473967C (en) * 2001-10-12 2011-06-14 Monosolrx Llc Thin film with non-self-aggregating uniform heterogeneity, process for their production and drug delivery systems made therefrom
ES2444951T5 (en) 2001-10-12 2022-06-28 Aquestive Therapeutics Inc Uniform films for a fast-dissolving dosage form incorporating taste-masking compositions
CA2523372A1 (en) 2003-05-02 2004-11-11 Warner-Lambert Company Llc Fast dissolving orally consumable films containing a modified starch for improved heat and moisture resistance
EP2161021B1 (en) * 2007-06-07 2017-03-08 Sato Pharmaceutical Co. Ltd. Medicinal film preparation with rapidly dissolving property and flexibility
WO2010086989A1 (en) 2009-01-29 2010-08-05 日東電工株式会社 Intraoral film-shaped base and preparation
WO2011090694A1 (en) * 2009-12-28 2011-07-28 Monosol Rx, Llc Orally administrable film dosage forms containing ondansetron
RU2562586C2 (en) * 2010-12-23 2015-09-10 Колгейт-Палмолив Компани Films and compositions, composing thereof

Similar Documents

Publication Publication Date Title
JP2016525572A5 (en)
JP2019147832A5 (en)
US8663659B2 (en) Orally administrable films
JP2010209104A5 (en)
JP5775223B2 (en) Granules for intraoral rapidly disintegrating tablets
JP6067687B2 (en) Edible oral strip or wafer dosage form containing ion exchange resin for taste masking
JP2018100286A (en) Corticosteroid composition for oral administration
JP2007528901A5 (en)
JP2016006108A5 (en)
WO2015016727A4 (en) Oral dispersible films
JP2020523335A5 (en)
RU2017101833A (en) ORAL DISPOSABLE FILM MEDIUM CONTAINING TADALAFIL AND METHOD FOR PREPARING IT
JP2013501717A5 (en)
PT2407166E (en) Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
JP2009521526A5 (en)
RU2014101990A (en) LIQUID PHARMACEUTICAL COMPOSITION INCLUDING NITIZINON
JP2018516266A5 (en)
US20130039967A1 (en) Oral dosage forms
KR101643572B1 (en) Orally disintegrating film containing high dose of drugs and method for preparing same
JP5952646B2 (en) Oral dissolution type film preparation
JP2016503066A5 (en)
TW201501731A (en) Enteric coated tablet
JP2020510660A5 (en)
FI4138789T3 (en) New delayed release composition for peroral administration
JP2010506855A5 (en)